The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an estimated USD 7 billion. Roivant Sciences reported in a press release that all existing institutional shareholders participated in the latest funding round....

In 2016, Roivant Sciences established their global headquarters in Basel. Roivant founder and CEO Vivek Ramaswamy talked to us about his fast growing company, his priorities for the company and about the role that Roivant aims to play in the Basel life sciences ecosystem. BaselArea.swiss: You built...